Kewalramani Reshma
CEO & President
Kewalramani Reshma has filed 6 SEC Form 4 filings (20 transaction rows) across 1 company, with disclosures dating back to 2026. 6 of those filings fall inside the rolling window. Most recent filing: Mar 3, 2026.
On the most recent filing, Kewalramani Reshma is listed as CEO & President at VERTEX PHARMACEUTICALS INC / MA. Inside the rolling window, Kewalramani Reshma reported no open-market purchases and 1 open-market sale totaling $19.7M in VRTX.
Companies traded
Other insiders at VRTX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$19.7M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Kewalramani Reshma made?
Kewalramani Reshma has filed 6 SEC Form 4 filings (20 transaction rows) across 1 company since 2026.
Which companies does Kewalramani Reshma trade?
Kewalramani Reshma has filed SEC Form 4 disclosures for 1 company, including VRTX.
When was Kewalramani Reshma's most recent SEC Form 4 filing?
Kewalramani Reshma's most recent SEC Form 4 filing on Tracefour is dated Mar 3, 2026.
What is Kewalramani Reshma's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Kewalramani Reshma is listed as CEO & President.
What is Kewalramani Reshma's total buy and sell value in the current window?
Inside the rolling retention window, Kewalramani Reshma bought $0 and sold $19.7M based on SEC Form 4 filings.
What was Kewalramani Reshma's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 40,000 VRTX shares on 2026-02-27, worth $19.7M, per SEC Form 4 filings.